Similarly, other inhibitors targeting enzymes responsible for adding and removing m6A mark (METTL and FTO proteins, respectively) have entered phase 1 clinical trials for AML in 2022 [164, 165]. The gene discussed is FTO; the disease is acute myeloid leukemia.